Navigation Menu

Scott Giacobello

Chief Financial Officer, Aadi Bioscience, Inc.


Scott Giacobello is the chief financial officer of Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Prior to joining Aadi in 2021, Mr. Giacobello played a key role in the buildout of U.S. operations and commercial readiness in his role as chief financial officer of GW Pharmaceuticals plc, leading the company’s financial strategy and raising more than $620 million ahead of its acquisition by Jazz Pharmaceuticals in 2021.  Mr. Giacobello is an accomplished executive with more than 25 years of experience leading finance organizations. Prior to GW, he served as chief financial officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, until it was acquired by Allergan in 2016. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as vice president of finance for global research & development. While at Allergan, he also served as vice president of corporate finance and vice president of internal audit & compliance.  Mr. Giacobello’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a B.A. in business administration from the University of Notre Dame and is a certified public accountant.